Suppr超能文献

高危神经母细胞瘤巩固治疗中转移病灶放疗:能否实现长期控制?

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

机构信息

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1204-1209. doi: 10.1016/j.ijrobp.2018.01.008. Epub 2018 Jan 9.

Abstract

PURPOSE

As part of consolidative therapy in high-risk neuroblastoma, modern protocols recommend radiation therapy (RT) both to the primary site and to sites of metastatic disease that persist after induction chemotherapy. Although there are abundant data showing excellent local control (LC) with 21 Gy directed at the primary site, there are few data describing the feasibility and efficacy of RT directed at metastatic sites of disease as part of consolidation.

METHODS AND MATERIALS

All patients with neuroblastoma who received RT to metastatic sites of disease as a part of consolidative therapy at a single institution between 2000 and 2015 were reviewed. Among 159 patients, 244 metastases were irradiated.

RESULTS

The median follow-up period among surviving patients was 7.4 years. Over 85% of the irradiated metastases were treated with 21 Gy (range, 10.5-36 Gy). Tumor recurrence occurred in 43 of 244 irradiated metastases (18%). The 5-year LC rate of treated metastatic sites was 81%. Metastatic sites that cleared with induction chemotherapy had improved LC compared with sites with persistent uptake on metaiodobenzylguanidine scans (LC rate, 92% vs 67%; P < .0001). LC at irradiated metastatic sites did not differ based on total number of sites irradiated or site of disease irradiated (bone vs soft tissue). Patients with bulky, resistant disease who were treated with 30 to 36 Gy had worse LC (P = .02). However, on multivariate analysis, only persistence after induction chemotherapy remained a significant prognostic factor for LC (hazard ratio, 3.7; P < .0001). Patients who had LC at irradiated metastatic sites had improved overall survival compared with those who did not (overall survival rate, 71% vs 50%; P < .0001).

CONCLUSIONS

Response to chemotherapy is an important prognostic factor for LC at irradiated metastatic sites in neuroblastoma. Overall, consolidative RT appears to be an effective modality of LC. Long-term disease control can be achieved with such an approach.

摘要

目的

在高危神经母细胞瘤的巩固性治疗中,现代方案建议对原发性肿瘤部位和诱导化疗后仍存在的转移性疾病部位进行放射治疗(RT)。尽管有大量数据显示,对原发性肿瘤部位给予 21 Gy 的定向照射可实现极好的局部控制(LC),但关于作为巩固性治疗一部分,对转移性疾病部位进行 RT 的可行性和疗效的数据却很少。

方法和材料

对 2000 年至 2015 年期间在单一机构接受转移性疾病部位 RT 作为巩固性治疗的神经母细胞瘤患者进行了回顾性分析。在 159 例患者中,有 244 个转移灶接受了放疗。

结果

在存活患者中,中位随访时间为 7.4 年。超过 85%的放射性转移灶接受了 21 Gy(范围 10.5-36 Gy)的治疗。在 244 个接受放疗的转移灶中,有 43 个(18%)出现肿瘤复发。治疗转移性疾病部位的 5 年 LC 率为 81%。经诱导化疗清除的转移灶与残留 131I-间碘苄胍摄取的转移灶相比,LC 率更高(92%比 67%;P<0.0001)。LC 与接受放疗的转移灶总数或部位(骨 vs 软组织)无关。接受 30-36 Gy 治疗的巨大、耐药性疾病患者的 LC 较差(P=0.02)。然而,在多变量分析中,只有诱导化疗后的残留情况仍然是 LC 的显著预后因素(风险比,3.7;P<0.0001)。在接受放疗的转移性疾病部位获得 LC 的患者与未获得 LC 的患者相比,总体生存率更高(总体生存率,71%比 50%;P<0.0001)。

结论

对化疗的反应是神经母细胞瘤中接受放疗的转移性疾病部位 LC 的重要预后因素。总的来说,巩固性 RT 似乎是一种有效的 LC 治疗方法。这种方法可以实现长期疾病控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fa5/5934297/d185e29c8b25/nihms933396f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验